The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 (https://www.sanofi.com/en/media-room/press-releases/2025/ ...

In 2024, Sanofi (NASDAQ:SNY) worked hard to become primarily a biopharma company, which included selling a dominant stake in Opella, a major company in the over-the-counter and vitamins ...

The iPhone 11 Pro is available in black, white, gold, and midnight green. Prices start at $999 for the 64GB version, $1149 for the 256GB, and $1349 for the 512GB variant.

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

In October 2024, Sanofi entered talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of Opella, valued at around $17bn. A deal is slated to be completed by Q2 this year.